CVAC News and Press, CureVac N.V. From 04/21/22

- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals - Technology adaptation for bivalent approach for COVI...

GlaxoSmithKline (NYSE:GSK) and CureVac (CVAC) signed an agreement with the German government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants Germany access to CureVac’s ma...

- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to ...

CureVac (NASDAQ:CVAC) said the first participant was dosed in a phase 1 study of second-generation mRNA vaccine for COVID-19, CV2CoV, developed in collaboration with GlaxoSmithKline (NYSE:GSK). The company said a preclinical study of CV2CoV in cynomolgus macaques, publishe...

Phase 1 dose-escalation study started at clinical sites in the U.S. Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /...

Gainers: Semtech Corporation (NASDAQ:SMTC) +4%. Forterra (NASDAQ:FRTA) +4%. Cerus Corporation (NASDAQ:CERS) +4%. Inspirato Incorporated (NASDAQ:ISPO) +4%. Infinera Corporation (NASDAQ:INFN) +4%. Losers: Codex DNA (NASDAQ:DNAY) -6%. CureVac  (NASDAQ:CVAC) -5%. CarParts...

CureVac (NASDAQ:CVAC) formed a new subsidiary called CureVac RNA Printer GmbH to advance its RNA Printer(R) technology which integrates and automates manufacturing for RNA vaccines and therapeutics. The company said the new entity is designed as a platform and services company, providing...

The RNA Printer (R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer (R) Dr. Markus Bergmann ...

CureVac (NASDAQ:CVAC) dosed the first person in a phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate CVSQIV, developed in collaboration with GlaxoSmithKline (NYSE:GSK). The company said the potential vaccine features multiple non-chemically modified mRNA con...

- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / ...